Freeline Therapeutics Holdings plc - ADR

NASDAQ:FRLN  
0.74
-0.01 (-1.33%)
Earnings Announcements

Freeline Reports Full Year 2021 Financial Results And Business Highlights

Published: 03/31/2022 20:31 GMT
Freeline Therapeutics Holdings plc - ADR (FRLN) - Freeline Reports Full Year 2021 Financial Results and Business Highlights.
Freeline Therapeutics Holdings - Expects Current Level of Cash and Cash Equivalents to Fund Operating Expenses Into Second Half of 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.50

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.48

More details on our Analysts Page.